Ordensklinikum Linz GmbH
Linz, Austria
5 recruiting
Showing 1–8 of 8 trials
Recruiting
Phase 3
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Metabolic dysfunction-associated steatohepatitis (MASH)Liver Fibrosis
Boehringer Ingelheim1,800 enrolled524 locationsNCT06632444
Recruiting
Phase 3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Metabolic Dysfunction-Associated Steatohepatitis
Boehringer Ingelheim1,590 enrolled443 locationsNCT06632457
Recruiting
Phase 3
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
Acute Myeloid Leukemia
University of Ulm650 enrolled91 locationsNCT04628026
Recruiting
Phase 3
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+3 more
Relay Therapeutics, Inc.540 enrolled120 locationsNCT06982521
Recruiting
Phase 3
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Multiple Myeloma
European Myeloma Network B.V.1,594 enrolled211 locationsNCT05243797
Recruiting
Phase 3
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
Cholangiocarcinoma
Servier Affaires Médicales220 enrolled84 locationsNCT05876754
Recruiting
Phase 2
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
Metastatic Colorectal Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest140 enrolled23 locationsNCT06856837
Recruiting
Phase 3
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
Cholangiocarcinoma
TransThera Sciences (Nanjing), Inc.200 enrolled87 locationsNCT05948475